Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada Approves GlucaGen
Paladin Labs has received approval from the Biologics and Genetic Therapies Directorate of Health Canada for GlucaGen (recombinant glucagon for injection). GlucaGen is indicated for the treatment of
Paladin Labs has received approval from the Biologics and Genetic Therapies Directorate of Health Canada for GlucaGen (recombinant glucagon for injection). GlucaGen is indicated for the treatment of
LEO Pharma is re-acquiring Warner Chilcott’s exclusive product licensing rights in the US to its topical psoriasis treatments Taclonex, Taclonex Scalp, Dovonex as well as rights to all
Sanofi Pasteur has approved the results of the collaborative HIV vaccine trial that has been conducted in Thailand over the past six years. The phase III clinical trial
Amgen has announced detailed results from the phase 3 ‘203’ trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic
Lundbeck’s partner Teva has announced that results from the ADAGIO trial, which demonstrated that Parkinson’s disease patients receiving Azilect (rasagiline) 1mg/day at the start of the study (early-start
Sartorius Stedim Biotech will launch the commercially available membrane adsorber for hydrophobic interaction chromatography (HIC). Sartobind Phenyl membrane adsorbers allow increased flow rates to ensure faster processes and
HRA Pharma has entered into an exclusive agreement with the Australian drug delivery company Acrux to market and distribute Acrux’s transdermal estradiol spray in France, Germany, the UK,
Genzyme has announced that its randomised phase 3 clinical trial investigating Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients
Galapagos has announced that its service division, BioFocus DPI, has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). As per the agreement, BioFocus DPI would perform
XOMA has expanded its biodefense programs to include the development of a novel antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to